SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ZymoGenetics ZGEN
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: DewDiligence_on_SI who wrote (169)4/27/2009 12:35:12 PM
From: tuck   of 210
 
Thanks for the pointers. I haven't had time to look at the posters yet. I guess, shock of shocks, the PR is a little spun. Nevertheless, VL reduction data is pretty strong. Do you know if there is a standard dose of Ribavirin in these combos and if ZGEN used it here? It would seem that, given lambda's immunological MOA, we might see a better therapeutic window with a lower than usual R dose in the combo. Aside from the VL reduction angle, I'm not going to get too excited one way or the other until we have larger samples to work with.

Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News